Sexual Dysfunction

Drugs and devices in the pipeline from Medivation, Astellas Pharma, Teva Pharmaceuticals, Boston Scientific, Northwest Biotherapeutics, and Generex Biotechnology.

New products and services from UroGPO, Caldera Medical, Auxilium Pharmaceuticals, VIVUS, and Jeffrey Albaugh, PhD, APRN.

Erectile dysfunction has been added the U.S. Surgeon General’s list of diseases caused by smoking.

A recently published study found that a small percentage of men who seek infertility treatment are potentially hurting their ability to have children by taking testosterone supplements.

Although testosterone use has increased significantly among older men in the past decade, many patients appear to have normal testosterone levels and do not meet the clinical guidelines for treatment, according to new research.

The latest products and services from Lambert Academic Publishing, the AUA, United Guardian, and SpryPublishing.

Researchers say they have linked high testosterone levels in men to a poor immune response to an influenza vaccine.

The FDA has approved collagenase clostridium histolyticum (CCH [XIAFLEX]) as the first medication to treat of Peyronie's disease (PD).

Data from phase III studies of collagenase clostridium histolyticum (CCH [XIAFLEX]) showed that the agent met primary endpoints related to Peyronie’s disease (PD) curvature and symptoms, and that it is effective and safe in certain subgroups of men with PD, according to Auxilium Pharmaceuticals, Inc.

The latest products and services from Mission Pharmacal, Eli Lilly, Richard Wolf Medical Instruments Corp., and Inspire on Purpose Publishing.

Older men with midrange testosterone levels tend to live longer compared with men who have low or high levels, Australian researchers say.

The FDA has approved a product label addition for the phosphodiesterase-type-5 inhibitor tadalafil (Cialis) that involves its use with finasteride (Proscar).

The latest products and services from SuperSonic Imagine, Auxilium Pharmaceuticals, VIVUS, the Centers for Medicare & Medicaid Services, Innovus Pharmaceuticals, Buffalo Filter, KRS Global Biotechnology, Demos Health, and Ethicon Endo-Surgery.

Insufficient estrogen levels in men may be at least partially to blame for symptoms that are often attributed to hypogonadism, according to a recently published study.

Some urologists are seeing more younger men for erectile dysfunction than they have in the past, the reasons for which appear to be multi-factorial.

Two California compounding pharmacies have announced voluntary recalls of testosterone products.

A new study has found that testosterone replacement doesn’t worsen lower urinary tract symptoms related to an enlarged prostate. In fact, many men saw their symptoms improve, apparently with little effect on their prostate gland.

The latest products and services from neoSurgical, Wiley-Blackwell, iURO, and USARAD.com.

Drugs and devices in the pipeline from Targacept, Inc., Cubist, OncoGenex Pharmaceuticals, Inc., Apricus Biosciences, and Nymox Pharmaceutical Corp.

A greater percentage of men who had an incomplete response to as-needed phosphodiesterase type-5 inhibitor treatment returned to normal erectile function when given tadalafil (Cialis) once daily, compared to placebo, researchers reported.

Robert C. Dean, MD, presents the take home messages on sexual function/dysfunction from the AUA annual meeting in San Diego.

Men using long-term, high-dose prescription opioids for back pain were about 50% more likely to be using medications for erectile dysfunction than men with back pain who were not using opioids, researchers reported.

Saying it’s time to take the guesswork out of buying a legitimate drug online and combat counterfeiters, Pfizer has launched a prescription-fulfillment website for the phosphodiesterase type-5 inhibitor sildenafil citrate (Viagra).

In the area of sexual dysfunction, much of the clinical research continues to focus on medical therapies, and this will be evident at the upcoming AUA annual meeting in San Diego.

Placement of an inflatable penile prosthesis (IPP) approximately 3 months after T-shunt surgery in men with acute ischemic priapism and refractory erectile dysfunction is associated with favorable outcomes at 1 year, according to data from a small series of such patients.